Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases

Ronan Flippot, Pamela Biondani, Edouard Auclin, Dingyu Xiao, Lizza Hendriks, Emilie Le Rhun, Charlotte Leduc, Michele Beau-Faller, Radj Gervais, Jordi Remon, Julien Adam, David Planchard, Pernelle Lavaud, Charles Naltet, Caroline Caramella, Cecile Le Pechoux, Ludovic Lacroix, Anas Gazzah, Laura Mezquita, Benjamin Besse*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Web of Science)
14 Downloads (Pure)
Original languageEnglish
Pages (from-to)1400-1407
Number of pages8
JournalJournal of Thoracic Oncology
Volume14
Issue number8
DOIs
Publication statusPublished - Aug 2019

Keywords

  • NSCLC
  • EGFR
  • Tyrosine kinase inhibitor
  • Leptomeningeal metastases
  • CELL LUNG-CANCER
  • DOSE WEEKLY ERLOTINIB
  • BRAIN METASTASES

Cite this